NVision Named Top 10 Finalist for The Spark: German Digital Award
Company
July 2, 2025
NVision Positioned as Key Enabler for Q-MRI Following EU’s Formalization of Quantum Europe Strategy
BRUSSELS, Belgium— The European Commission has formalized its Quantum Europe Strategy, listing Quantum-Enhanced MRI (Q-MRI) as a core priority for global leadership by 2030.
NVision's POLARIS platform provides the necessary room-temperature hyperpolarization technology to enable Q-MRI to be technically feasible and scalable in clinical settings. The alignment of POLARIS with this strategic mandate contributes to providing non-invasive, real-time metabolic insights as a "Made in Europe" quantum solution for global health.
Learn more ↗
Read more
POLARIS
Company
October 23, 2025
German Flagship Project Annual Meeting: Building an End-to-End Clinical Platform for Quantum-Enhanced Metabolic MRI
ULM, Germany - We joined the annual General Assembly of QuE-MRT, for a day focused on discussions and updates for advancing metabolic imaging.
This German flagship project is focused on building an end-to-end clinical platform for quantum-enhanced hyperpolarized metabolic MRI, including R&D work on the polarizer and MRI acquisition methods, preclinical research on cancer models, regulatory effort towards clinical studies in Germany and ultimately running clinical studies on 3 different cancer patient populations.
Once again, we were impressed by the progress happening on so many fronts:
- Standardized MRI acquisition protocols enabling broader adoption
- New, promising metabolic probes (like Z-OMPD and α-KIC)
- Key advances in the regulatory process toward the first clinical HP-MRI studies in Germany
Read more
POLARIS